In July 2008, Raven Biotechnologies Inc was acquired by MacroGenics, Inc,. Raven Biotechnologies had been focused on the rapid discovery of functionally validated cell-surface targets, and the development of monoclonal antibodies (MAbs) or other therapeutics to regulate them. Raven's integrated approach is based on proprietary, human tissue-specific progenitor and tumor cell lines developed at Raven, plus proprietary methods optimized for producing monoclonal antibodies (MAbs) targeting cell surface proteins. This platform rapidly identifies target antigens and therapeutic candidates in their native configuration in the intact cell membrane. The company has identified candidate therapeutic MAbs for lung, colon, pancreatic, prostate, breast, brain and ovarian cancer, and has a partnership with ImmunoGen for the discovery and development of therapeutic MAbs for ovarian cancer.
